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concluded that aprotinin use was the factor
associated with mortality when comparing
data from 1343 aprotinin-treated patients
with those from 6776 given EACA and
2029 given neither therapy.
Two aspects may lead the interested
reader to question this conclusion. First,
the propensity analysis did not include red
blood cell transfusion numbers as a factor
(transfusion was graded as either yes or
no). More worrisome is that a matched-pairs
analysis was relegated to the supplementary
data available online from the New England
Journal of Medicine. In this analysis, which
included 1992 patients with comparable
risks, aprotinin showed no effects on 30-
day (P 5 .58) and 1-year mortalities (P 5
.36) relative to EACA.
Thus if propensity scoring is achieved by
linear regression, and confounding variables
known to be associated with adverse out-
comes are excluded, then observational
studies show aprotinin to be a dangerous
drug. Aprotinin is not seen to be dangerous,
however, when the analysis is performed
with matching or stratification of risk and
known confounders are included.
David Royston, FRCA
Consultant Anaesthetist
Royal Brompton and Harefield NHS Trust
Harefield, UK
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Reply to the Editor:
I appreciate Dr Royston’s kind comment re-
garding my editorial. I am quite certain that
he agrees with me that we are ‘‘worse off
without [aprotinin] in our arsenal.’’ Indeed,
I feel this sentiment particularly this even-
ing, as I wait for a call from the operating
room to start repair of an acute dissection
in an 80-year-old patient who is receiving
warfarin 5 years after coronary bypass and
aortic valve replacement. I am also sure
that he agrees that, in the best of all possible
worlds, the risks and benefits determining
the use of a drug should pertain to the wel-
fare of the patient as judged by physicians
and not to the litigation risks of a pharmaceu-
tical company as judged by lawyers.
I also appreciate Dr Royston’s comments
regarding bias. The biases of which he
speaks have not (entirely) escaped me; all
studies have biases. Randomized studies
are of necessity biased at entry. Rigid eligi-
bility criteria are necessary to define a popu-
lation with sufficient precision to permit
analysis, and the demands of equipoise
encourage inclusion of low-risk patients for
whom harm is the least likely–but so is ben-
efit. Consequently, few such studies truly re-
flect the spectrum of disease that we face in
clinical practice. The populations included
in observational studies are more representa-
tive of practice; however, the bias introduced
by the clinical judgments made in the appli-
cation of a therapy or administration of
a drug impose considerable challenges to
balanced interpretation, as so beautifully
demonstrated in Dr Royston’s letter. I could
not agree more. As noted in his comments,
understanding the appropriate application
and interpretation of propensity analysis de-
mands a learned understanding of the
methods as well as the aims of the matching.
Unfortunately, few of us (certainly not I) are
so statistically sophisticated. I know that in
this regard Dr Royston can run circles
around me. No contest.
In the end, where we differ, it would
appear, is regarding just where the rest of
the medical community is struggling. What
are the real risks associated with aprotinin?
Is it ‘‘a potentially harmful drug’’? If so,
what is the magnitude of that risk? Person-
ally, I remain amazed that today (May
23, 2008), with more than 7100 citations
now retrievable on a PubMed search for
aprotinin, there is still room for debate.
Thoralf M. Sundt, MD
Division of Cardiovascular Surgery
Mayo Clinic
Rochester, Minn
doi:10.1016/j.jtcvs.2008.06.005
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Re: A near-fatal presentation of a bronchogenic cyst compressing the left main coronary artery. J Thorac Cardi-
ovasc Surg. 2008;135:1395-6.
In the above-noted article, Dr Malcom Finlay should have been listed as the second author on the article. Dr Finlay
was the admitting physician in the case. He supplied the angiographic image of the left main stem (LMS) compres-
sion (acting as operator) and transoesophageal echo (TOE) image, and he also obtained the patient’s consent for
publication.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 3 799
